22.

Third-generation inhibitor having higher potency in resistant

cell lines than gefitinib

Mowafy

et al. (2016)

23.

First-generation inhibitor and also inhibits mutated cell lines

reversibly and non-selectively

Shao et al.

(2016)

24.

Third-generation inhibitor. Highly selective activity for

mutated strains of EGFR as compared to wild type

Song et al.

(2019)

25.

Second-generation inhibitor. Lower potency but better activity

as compared to afatinib

Tu et al.

(2016)

21

EGFR-Targeted Quinazoline Clubbed Heterocycles as Anticancer Agents

393